share_log

Halozyme Therapeutics's Earnings: A Preview

Halozyme Therapeutics's Earnings: A Preview

Halozyme Treateutics公司的收益预览
Benzinga Real-time News ·  2021/02/22 23:07

Halozyme Therapeutics (NASDAQ:HALO) releases its next round of earnings this Tuesday, February 23. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.

卤酶治疗学(纳斯达克:光晕)将于2月23日(星期二)公布下一轮财报。在Benzinga公司第四季度收益报告的基本指南中获得最新的预测。

Net Income, Earnings, And Earnings Per Share

净收入、收益和每股收益

Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.

收益和每股收益是衡量盈利能力的有用指标。总收入,也称为净收入,等于总收入减去总支出。净利润除以流通股总数得出每股收益。

Earnings And Revenue

收入和收入

Halozyme Therapeutics EPS is expected to be around $0.53, according to sell-side analysts. Sales will likely be near $120.16 million. In the same quarter last year, Halozyme Therapeutics reported EPS of $0.24 on revenue of $53.66 million.

据卖方分析师称,Halozyme治疗公司的每股收益预计在0.53美元左右。销售额可能接近1.2016亿美元。去年同一季度,Halozyme治疗公司报告每股收益为0.24美元,营收为5366万美元。

What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter?

分析师的预期和收益惊喜是什么?为什么它们很重要?

Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin.

负责该公司业务的分析师将每季度发布对其收入和每股收益的前瞻性估计。把每个分析师对一家公司一个季度的每股收益和营收预测加在一起,得出的是“共识估计”。一家公司公布的收益或收入高于或低于普遍预期,这被称为“收益惊喜”,可能会使股价大幅波动。

If the company were to match the consensus estimate, earnings would be up 320.83%. Revenue would be up 123.91% from the year-ago period. Here is how the company's reported EPS has stacked up against analyst estimates in the past:

如果该公司达到普遍预期,收益将增长320.83%。营收将比去年同期增长123.91%。以下是该公司过去公布的每股收益与分析师预期的对比情况:

Quarter Q3 2020 Q2 2020 Q1 2020 Q4 2020
EPS Estimate 0.20 0.25 -0.02 -0.15
EPS Actual 0.25 0.19 -0.04 -0.24
Revenue Estimate 60.91 M 66.68 M 42.96 M 56.93 M
Revenue Actual 65.32 M 55.22 M 25.35 M 53.66 M
季度 Q3 2020 Q2 2020 Q1 2020 Q4 2020
每股收益预估 0.20 0.25 -0.02 -0.15
实际每股收益 0.25 0.19 -0.04 -0.24
收入预估 60.91 M 66.68 M 42.96 M 56.93 M
实际收入 65.32 M 55.22 M 25.35 M 53.66 M

Stock Performance

股票表现

Shares of Halozyme Therapeutics were trading at $49.68 as of February 19. Over the last 52-week period, shares are up 139.13%. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release.

截至2月19日,Halozyme Treeutics的股价为49.68美元。在过去52周内,股价上涨了139.13%。考虑到这些回报总体上是积极的,长期股东应该对此次收益发布感到满意。

Do not be surprised to see the stock move on comments made during its conference call. Halozyme Therapeutics is scheduled to hold the call at 16:30:00 ET and can be accessed here.

如果看到该股在电话会议期间发表的评论出现波动,不要感到惊讶。Halozyme Treeutics计划在美国东部时间16:30:00举行电话会议,可以访问这里.

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发